Marshall W. Fordyce

3.0k total citations · 1 hit paper
30 papers, 1.8k citations indexed

About

Marshall W. Fordyce is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Marshall W. Fordyce has authored 30 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 18 papers in Virology and 14 papers in Emergency Medicine. Recurrent topics in Marshall W. Fordyce's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (18 papers) and HIV-related health complications and treatments (14 papers). Marshall W. Fordyce is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (18 papers) and HIV-related health complications and treatments (14 papers). Marshall W. Fordyce collaborates with scholars based in United States, United Kingdom and Japan. Marshall W. Fordyce's co-authors include Tomáš Cihlář, Adrian S. Ray, Michael J. M. Hitchcock, Christian Callebaut, Andrew Cheng, Lijie Zhong, Scott McCallister, Edwin DeJesus, Frank A. Post and Michael E. Abram and has published in prestigious journals such as Journal of the American Society of Nephrology, Antimicrobial Agents and Chemotherapy and Quality of Life Research.

In The Last Decade

Marshall W. Fordyce

30 papers receiving 1.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus

2015 309 citations Adrian S. Ray, Marshall W. Fordyce et al. Antiviral Research profile →

Peers

Countries citing papers authored by Marshall W. Fordyce

Since Specialization

Citations

This map shows the geographic impact of Marshall W. Fordyce's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marshall W. Fordyce with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marshall W. Fordyce more than expected).

Fields of papers citing papers by Marshall W. Fordyce

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marshall W. Fordyce. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marshall W. Fordyce. The network helps show where Marshall W. Fordyce may publish in the future.

Co-authorship network of co-authors of Marshall W. Fordyce

This figure shows the co-authorship network connecting the top 25 collaborators of Marshall W. Fordyce. A scholar is included among the top collaborators of Marshall W. Fordyce based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marshall W. Fordyce. Marshall W. Fordyce is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Risks associated with antiretroviral treatment for human immunodeficiency virus (HIV): qualitative analysis of social media data and health state utility valuation 2017 ·Quality of Life Research ·Louis S. Matza, Karen Chung, (unknown), Trena M. Paulus, Evan Davies, Katie D. Stewart, Grace A. McComsey, Marshall W. Fordyce	7
2	Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide 2016 ·EBioMedicine ·Nicholas Funderburg, Grace A. McComsey, Manjusha Kulkarni, Tammy Bannerman, (unknown), (unknown), Hui C. Liu, Yafeng Zhang, Qinghua Song, Liang Fang, Jason B. Dinoso, Andrew Cheng, Scott McCallister, Marshall W. Fordyce, Moupali Das	19
3	Rare emergence of drug resistance in HIV-1 treatment -naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide 2016 ·HIV Clinical Trials ·Nicolas Margot, Kathryn M. Kitrinos, Marshall W. Fordyce, Scott McCallister, Michael D. Miller, Christian Callebaut	12
4	Brief Report 2016 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·David A. Wohl, Shinichi Oka, Nathan Clumeck, Amanda Clarke, (unknown), Jeffrey L. Stephens, Karen T. Tashima, José Ramón Arribas, Bruce Rashbaum, Antoine Chéret, Jason Brunetta, Cristina Mussini, Pablo Tebas, Paul E. Sax, Andrew Cheng, Lijie Zhong, Christian Callebaut, Moupali Das, Marshall W. Fordyce	145
5	Pharmacokinetics of Co-Formulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate After Switch From Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Healthy Subjects 2016 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Srini Ramanathan, Joseph M. Custodio, Xuelian Wei, Hui Wang, Marshall W. Fordyce, (unknown), Kah Hiing John Ling, Javier Szwarcberg, Brian P. Kearney	10
6	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment: 48-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study 2016 ·LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, (unknown), Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	12
7	Current status and prospects of HIV treatment 2016 ·Current Opinion in Virology ·Tomáš Cihlář, Marshall W. Fordyce	230
8	Brief Report: Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Adults With Renal Impairment: 96-Week Results From a Single-Arm, Multicenter, Open-Label Phase 3 Study 2016 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Frank A. Post, Pablo Tebas, Amanda Clarke, Laurent Cotte, William R. Short, Michael E. Abram, Shuping Jiang, Andrew Cheng, Moupali Das, Marshall W. Fordyce	53
9	P030: Renal and bone safety of tenofovir alafenamide versus tenofovir disoproxil fumarate 2015 ·Journal of the International AIDS Society ·Edwin DeJesus, (unknown), Michael T. Yin, Frank Post, Shinichi Oka, Ellen Koenig, Benoît Trottier, Jaime Andrade‐Villanueva, Huyen Cao, (unknown), Marshall W. Fordyce	9
10	Switching to Tenofovir Alafenamide, Coformulated With Elvitegravir, Cobicistat, and Emtricitabine, in HIV-Infected Patients With Renal Impairment 2015 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Anton Pozniak, José Ramón Arribas, Joseph Gathe, Samir K. Gupta, Frank A. Post, (unknown), Anchalee Avihingsanon, Gordon Crofoot, Paul Benson, Kenneth Lichtenstein, Moti Ramgopal, Ploenchan Chetchotisakd, Joseph M. Custodio, Michael E. Abram, Xuelian Wei, Andrew Cheng, Scott McCallister, Devi SenGupta, Marshall W. Fordyce	158
11	Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus breakdown → 2015 ·Antiviral Research ·Adrian S. Ray, Marshall W. Fordyce, Michael J. M. Hitchcock	309
12	Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy 2014 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Paul E. Sax, Andrew Zolopa, Indira Brar, Richard Elion, Roberto Ortiz, Frank A. Post, Hui Wang, Christian Callebaut, Hal Martin, Marshall W. Fordyce, Scott McCallister	165
13	Week 144 Resistance Analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Versus Atazanavir+Ritonavir+Emtricitabine/Tenofovir DF in Antiretroviral-Naïve Patients 2014 ·HIV Clinical Trials ·Rima Kulkarni, Michael E. Abram, Damian J. McColl, Tiffany Barnes, Marshall W. Fordyce, Javier Szwarcberg, Andrew Cheng, Michael D. Miller, Kirsten White	21
14	Cobicistat-boosted darunavir in HIV-1-infected adults: week 48 results of a Phase IIIb, open-label single-arm trial 2014 ·AIDS Research and Therapy ·Karen T. Tashima, Gordon Crofoot, Frank Tomaka, Thomas N. Kakuda, (unknown), Tom Van de Casteele, Magda Opsomer, (unknown), Nicolas Margot, Joseph M. Custodio, Marshall W. Fordyce, Javier Szwarcberg	48
15	Antiviral Activity, Safety, and Pharmacokinetics/Pharmacodynamics of Tenofovir Alafenamide as 10-Day Monotherapy in HIV-1–Positive Adults 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Peter Ruane, Edwin DeJesus, Daniel Berger, Martin Markowitz, U. Fritz Bredeek, Christian Callebaut, Lijie Zhong, Srini Ramanathan, Martin S. Rhee, Marshall W. Fordyce, Kitty Yale	247
16	A Randomized, Double-Blind Comparison of Coformulated Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF vs Ritonavir-Boosted Atazanavir Plus Coformulated Emtricitabine and Tenofovir DF for Initial Treatment of HIV-1 Infection 2013 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Jürgen K. Rockstroh, Edwin DeJesus, Keith Henry, Jean‐Michel Molina, Joseph Gathe, S. Ramanathan, Xuelian Wei, Andrew Plummer, Michael E. Abram, Andrew Cheng, Marshall W. Fordyce, Javier Szwarcberg	97
17	Anti-CD4 Monoclonal Antibody Ibalizumab Exhibits Breadth and Potency Against HIV-1, With Natural Resistance Mediated by the Loss of a V5 Glycan in Envelope 2012 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Craig S. Pace, Marshall W. Fordyce, David Franco, (unknown), Michael S. Seaman, David D. Ho	64
18	Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) has durable efficacy and differentiated safety compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF at week 96 in treatment‐naïve HIV‐1‐infected patients 2012 ·Journal of the International AIDS Society ·(unknown), E DeJesus, Kenneth R. Henry, Jean‐Michel Molina, Joseph Gathe, (unknown), Marshall W. Fordyce, Martin S. Rhee, Javier Szwarcberg	10
19	Giant Right Atrial Wall Vegetation Mimicking Cardiac Tumor 2007 ·Journal of the American Society of Echocardiography ·(unknown), Marshall W. Fordyce, Monvadi B. Srichai, (unknown), Mariela Losada, Samyra El‐ftesi, Timothy J. Vittorio, Juan B. Grau	6
20	Fertility of sheep given antisera to steroids during anoestrus 1983 ·Reproduction ·R. B. Land, Marshall W. Fordyce, I. K. Gauld, B. A. Morris, R. Webb	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact